Suboxone Patient Pharmacist Agreement

View Our Certificate
NSF

Suboxone Patient Pharmacist Agreement

Source: Isaac, P., Janecek, E, Kalvik, A. and Zhang, M. (2015). Opioid Agonist Maintenance Treatment: A chief pharmacist for methadone and buprenorphine for opioid use disorder. Toronto: Centre for Addiction and Mental Health. These forms are reproduced from maintenance agonist agonists: A pharmacists` guide to methadone and buprenorphine for opioid use disorders The pharmacist-patient treatment agreement treats the hours of remission and dosage procedures observed. It also helps pharmacists discuss concerns and implications around alcohol and other sedative drugs with patients at the beginning of their treatment program and minimize the likelihood of introducing patients who are poisoned by the pharmacy. When first distributing doses taken at home, the pharmacist should discuss the safe use and storage of the drug with the patient and document this discussion. Pharmacists are encouraged to have patients sign a written agreement, such as the samples provided here, to ensure that prevention and expectations are clearly understood.